At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 237 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised, Double-blind, 52-wk, Parallel-grp Multicentre, PIIb Study to Evaluate Effects of Rosuvastatin 10mg, Rosuvastatin 40mg and Atorvastatin 80mg on Urinary Protein Excretion in Hypercholesterolaemic Non-diabetic Patients With Moderate Proteinuria
In Brief
A Phase 2 clinical trial evaluating Rosuvastatin and Atorvastatin for Hyperlipidemia. Completed, enrolled 237 participants across 107 sites in 11 countries.
Detailed Summary
The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperlipidemia
CountriesBrazil, Bulgaria, Canada, Denmark, Germany, Hungary, Italy, Mexico, Romania, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2006
First PostedFeb 2006
Primary CompletionJun 2009
TodayJul 2026
First PostedFeb 27, 2006
Enrollment StartFeb 1, 2006
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.3 years ago
Interventions
Rosuvastatindrug
Atorvastatindrug